Diverse Subtypes of Cardiovascular Disease Risk Evaluated by Novel PREVENT Associated with Different Polycyclic Aromatic Hydrocarbon Metabolites.
- Author:
Ye XIN
1
;
Yu Cheng SUN
1
;
Lin CHEN
1
;
Feng Tao CUI
2
;
Ying Ge DUAN
1
;
Han Yun WANG
1
;
Li CHEN
1
;
Tian CHEN
1
;
Pi Ye NIU
1
;
Jun Xiang MA
1
Author Information
- Publication Type:Journal Article
- Keywords: Cardiovascular disease; NHANES; PREVENT equation; Polycyclic aromatic hydrocarbon
- MeSH: Humans; Cardiovascular Diseases/chemically induced*; Middle Aged; Polycyclic Aromatic Hydrocarbons/metabolism*; Male; Female; Adult; Aged; Risk Factors; China/epidemiology*
- From: Biomedical and Environmental Sciences 2025;38(10):1217-1229
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To investigate the association of various polycyclic aromatic hydrocarbon (PAH) metabolites with diverse subtypes of cardiovascular disease (CVD) risk.
METHODS:A novel predicting risk of cardiovascular disease EVENTs PREVENT equation was used to estimate the 10-year diverse subtypes of CVD risk, and their associations with PAH metabolites were analyzed using multiple logistic regression models, the weighted quantile sum (WQS) model, the quantile g-computation (qgcomp) model, and a stratified analysis of subgroups.
RESULTS:For this study, six thousand seven hundred and forty-five participants were selected, and significant positive associations were observed between PAHs, naphthalene (NAP), and fluorene (FLU), and the risks of total CVD, atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF). NAP and FLU were the primary contributors to the effects of PAH mixtures, and their associations with total CVD, ASCVD, and HF risk were significant in younger participants (30 ≤ age < 50 years); however, the associations of phenanthrene (PHEN) with ASCVD, HF, coronary heart disease (CHD), and stroke were dominant in aging participants (age ≥ 50 years). Notably, pyrene (PYR) was negatively associated with the risk of ASCVD, HF, CHD, and stroke. Similarly, negative associations of PYR with the four CVD subtypes were noticeable in aging participants.
CONCLUSION:Different PAHs metabolites had different impacts on each CVD subtype among different age groups. Notably, the protective effects of PYR on ASCVD, HF, CHD, and stroke were noticeable in aging individuals.
